
Commentary|Videos|December 13, 2024
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
Author(s)Maxwell Lloyd, MD
Fact checked by: Ashling Wahner , Chris Ryan
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.
Advertisement
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center, discusses findings from a real-world study investigating the effects of prior treatment, ESR1 mutation status, and PI3K pathway mutation status on outcomes with elacestrant (Orserdu) monotherapy in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5




































